Back to top
more

Seattle Genetics, Inc. (SGEN)

(Delayed Data from NSDQ)

$67.25 USD

67.25
574,388

+0.33 (0.49%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.27 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Merck (MRK), Seagen Drug Combo Gets FDA Nod for Bladder Cancer

by Zacks Equity Research

The combination of Merck's (MRK) Keytruda and Seagen's (SGEN) Padcev is the first approved immunotherapy and an antibody-drug conjugate for locally advanced or metastatic urothelial carcinoma.

Amicus Therapeutics (FOLD) Down 14% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

CRISPR Therapeutics AG (CRSP) Down 13.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Seattle Genetics (SGEN) Up 24.6% Since Last Earnings Report?

by Zacks Equity Research

Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates

by Kinjel Shah

Pfizer (PFE) is set to buy Seagen (SGEN) for $43 billion while Sanofi (SNY) is acquiring Provention Bio. Novo Nordisk (NVO) and Sanofi are looking to cut insulin prices.

Biotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & More

by Zacks Equity Research

Acadia's (ACAD) pipeline and regulatory updates, and Seagen's (SGEN) acquisition news are the key highlights from the biotech sector during the past week.

Shaun Pruitt headshot

Should Investors Consider Pfizer (PFE) or Seagen (SGEN) Stock After Acquisition

by Shaun Pruitt

Shares of Seagen (SGEN) popped 14% yesterday on news that Pfizer (PFE) would acquire the company for $43 billion. The deal values Seagen shares at $229 and 15% above current levels.

Pfizer (PFE) to Buy Seagen for $43B, Boost Cancer Portfolio

by Zacks Equity Research

Pfizer (PFE) is set to buy Seagen (SGEN) in a $43 billion deal. Seagen's key products focus on cancer treatment.

Company News for Mar 14, 2023

by Zacks Equity Research

Companies In The News Are: SGEN, PFE, PODD, SIVB, ILMN, PNC.

Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up

by Zacks Equity Research

Seagen is set to be acquired by the large-cap pharma company, Pfizer, at a valuation of $43 billion. The stock is up about 15% in response to the news.

Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?

by Zacks Equity Research

Seattle Genetics (SGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Ethan Feller headshot

Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma Acquisitions

by Ethan Feller

Last week ended on a hectic note...

Company News for Feb 28, 2023

by Zacks Equity Research

Companies in The News Are: UNP, TSLA, SGEN, PFE, NFLX

Durable Goods Orders Come in Nearly at a Three-Year Low

by Zacks Equity Research

Durable Goods Orders Come in Nearly at a Three-Year Low.

Mark Vickery headshot

Durables Goods Sink -4.5%, but Higher on Business Spending

by Mark Vickery

These Durable Goods figures are preliminary, and subject to future revisions.

Seagen (SGEN) Likely to be Acquired by Pfizer Claims WSJ

by Zacks Equity Research

Seagen (SGEN) may be acquired by the large-cap pharma company Pfizer at a valuation of more than $30 billion, according to a Wall Street Journal article. Seagen's stock is up 17% in pre-market hours in response to the news.

Seagen's (SGEN) Q4 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Seagen (SGEN) reports better-than-expected results in the fourth quarter of 2022, beating both earnings and sales estimates. Stock up in the after-market hours in response to the news.

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 21.57% and 9.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Seattle Genetics (SGEN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 Biotech Stocks Set to Outpace Q4 Earnings Estimates

by Zacks Equity Research

Let us look at some biotech stocks, ALLO, EDIT, NTLA and SGEN that are poised to beat on fourth-quarter earnings.